StreetInsider.com News Articles

Edwards Lifesciences (EW) PT Raised to $99 at Bernstein SocGen Group

Fri, 24 Jul 2026 08:39:57 -0400

(Updated - July 24, 2026 8:39 AM EDT)

Bernstein SocGen Group analyst Lee Hambright raised the price target on Edwards Lifesciences (NYSE: EW) to $99.00 (from $96.00) while maintaining a Market Perform rating.

The analyst commented: "Clean quarter; safe from medtech meltdown; Strong Q2, as sales grew 12.5% organic to $1.74bn, beating consensus by 2.5%. Adj EPS of $0.78 grew 16% and beat consensus ($0.74) by 5%, driven by the revenue beat and planned phasing of R&D and SG&A spend. Management reiterated confidence in average total company sales growth of around 10% over the longer term. Maintained EPS guidance. EW raised FY26

Edwards Lifesciences (EW) PT Raised to $99 at Bernstein SocGen Group

Fri, 24 Jul 2026 08:39:57 -0400

(Updated - July 24, 2026 8:39 AM EDT)

Bernstein SocGen Group analyst Lee Hambright raised the price target on Edwards Lifesciences (NYSE: EW) to $99.00 (from $96.00) while maintaining a Market Perform rating.

Edwards Lifesciences (EW) PT Raised at Piper Sandler After 'Another Clean Beat-And-Raise Print'

Fri, 24 Jul 2026 07:53:53 -0400

(Updated - July 24, 2026 7:53 AM EDT)

Piper Sandler analyst Adam Maeder raised the price target on Edwards Lifesciences (NYSE: EW) to $101.00 (from $100.00) while maintaining an Overweight rating.

The analyst commented: "Another Clean Beat-And-Raise Print; Multiple Catalysts On-The-Horizon; EW reported strong 2Q results tonight, with beats across all revenue segments. WW TAVR revenue increased +10.5% y/y ex-FX to $1.26B, comfortably above the Street's $1.23B estimate. Robust top-line performance combined with an adj. op margin beat drove Q2 adj. EPS of $0.78 versus consensus of $0.75. Given the results and underlying business momentum, EW raised its FY26 top-line guidance to

Edwards Lifesciences (EW) PT Raised at Piper Sandler After 'Another Clean Beat-And-Raise Print'

Fri, 24 Jul 2026 07:53:53 -0400

(Updated - July 24, 2026 7:53 AM EDT)

Piper Sandler analyst Adam Maeder raised the price target on Edwards Lifesciences (NYSE: EW) to $101.00 (from $100.00) while maintaining an Overweight rating.

Edwards Lifesciences (EW) PT Raised to $105 at JPMorgan

Fri, 24 Jul 2026 07:27:18 -0400

JPMorgan analyst Robbie Marcus raised the price target on Edwards Lifesciences (NYSE: EW) to $105.00 (from $100.00) while maintaining a Overweight rating.

Edwards Lifesciences (EW) PT Raised to $103 at Deutsche Bank

Fri, 24 Jul 2026 07:23:56 -0400

Deutsche Bank analyst Pito Chickering raised the price target on Edwards Lifesciences (NYSE: EW) to $103.00 (from $100.00) while maintaining a Buy rating.

Leerink Upgrades Edwards Lifesciences (EW) to Outperform

Fri, 24 Jul 2026 06:30:06 -0400

(Updated - July 24, 2026 6:30 AM EDT)

Leerink analyst Mike Kratky upgraded Edwards Lifesciences (NYSE: EW) from Market Perform to Outperform with a price target of $101.00 (from $87.00).

The analyst commented: "We are upgrading EW to Outperform from Market Perform and increasing our PT to $101 from $87. We have been Market Perform on EW since initiating coverage in October 2023, but have finally seen enough to justify an upgrade. EW posted strong 2Q26 results across the board, reinforcing this as the cleanest large-cap MedTech story, in our view. More importantly, looking ahead, EW checks nearly all the boxes: 1)

Leerink Upgrades Edwards Lifesciences (EW) to Outperform

Fri, 24 Jul 2026 06:30:06 -0400

(Updated - July 24, 2026 6:30 AM EDT)

Leerink analyst Mike Kratky upgraded Edwards Lifesciences (NYSE: EW) from Market Perform to Outperform with a price target of $101.00 (from $87.00).

Leerink Upgrades Edwards Lifesciences (EW) to Outperform

Fri, 24 Jul 2026 06:30:06 -0400

(Updated - July 24, 2026 6:30 AM EDT)

Leerink analyst Mike Kratky upgraded Edwards Lifesciences (NYSE: EW) from Market Perform to Outperform with a price target of $101.00 (from $87.00).

After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK

Thu, 23 Jul 2026 16:38:38 -0400

After-Hours Stock Movers:

Intel (NASDAQ: INTC)

Intel jumped 12% after delivering blowout Q2 results, posting an EPS of $0.42 (doubling Wall Street estimates of $0.21) on $16.13 billion in revenue. Management projected strong momentum to continue into Q3, guiding revenue to $15.8–$16.8 billion against a $15.1 billion consensus, propelled by accelerating AI-driven compute demand across its CPU and foundry franchises.

The blowout report lifted CPU rivals AMD and Arm Holdings in after-hours trading as investors cheered a broader recovery in PC and server chip demand.

MaxLinear (NASDAQ: MXL)

MaxLinear fell 7% despite topping Q2 estimates and issuing remarkably strong Q3 guidance, projecting revenue of

After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK

Thu, 23 Jul 2026 16:38:38 -0400

After-Hours Stock Movers:

Intel (NASDAQ: INTC)

The blowout report lifted CPU rivals AMD and Arm Holdings in after-hours trading as investors cheered a broader recovery in PC and server chip demand.

MaxLinear (NASDAQ: MXL)

MaxLinear fell 7% despite topping Q2 estimates and issuing remarkably strong Q3 guidance, projecting revenue of

After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK

Thu, 23 Jul 2026 16:38:38 -0400

After-Hours Stock Movers:

Intel (NASDAQ: INTC)

The blowout report lifted CPU rivals AMD and Arm Holdings in after-hours trading as investors cheered a broader recovery in PC and server chip demand.

MaxLinear (NASDAQ: MXL)

MaxLinear fell 7% despite topping Q2 estimates and issuing remarkably strong Q3 guidance, projecting revenue of

After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK

Thu, 23 Jul 2026 16:38:38 -0400

After-Hours Stock Movers:

Intel (NASDAQ: INTC)

The blowout report lifted CPU rivals AMD and Arm Holdings in after-hours trading as investors cheered a broader recovery in PC and server chip demand.

MaxLinear (NASDAQ: MXL)

MaxLinear fell 7% despite topping Q2 estimates and issuing remarkably strong Q3 guidance, projecting revenue of

After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK

Thu, 23 Jul 2026 16:38:38 -0400

After-Hours Stock Movers:

Intel (NASDAQ: INTC)

The blowout report lifted CPU rivals AMD and Arm Holdings in after-hours trading as investors cheered a broader recovery in PC and server chip demand.

MaxLinear (NASDAQ: MXL)

MaxLinear fell 7% despite topping Q2 estimates and issuing remarkably strong Q3 guidance, projecting revenue of

After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK

Thu, 23 Jul 2026 16:38:38 -0400

After-Hours Stock Movers:

Intel (NASDAQ: INTC)

The blowout report lifted CPU rivals AMD and Arm Holdings in after-hours trading as investors cheered a broader recovery in PC and server chip demand.

MaxLinear (NASDAQ: MXL)

MaxLinear fell 7% despite topping Q2 estimates and issuing remarkably strong Q3 guidance, projecting revenue of

After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK

Thu, 23 Jul 2026 16:38:38 -0400

After-Hours Stock Movers:

Intel (NASDAQ: INTC)

The blowout report lifted CPU rivals AMD and Arm Holdings in after-hours trading as investors cheered a broader recovery in PC and server chip demand.

MaxLinear (NASDAQ: MXL)

MaxLinear fell 7% despite topping Q2 estimates and issuing remarkably strong Q3 guidance, projecting revenue of

After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK

Thu, 23 Jul 2026 16:38:38 -0400

After-Hours Stock Movers:

Intel (NASDAQ: INTC)

The blowout report lifted CPU rivals AMD and Arm Holdings in after-hours trading as investors cheered a broader recovery in PC and server chip demand.

MaxLinear (NASDAQ: MXL)

MaxLinear fell 7% despite topping Q2 estimates and issuing remarkably strong Q3 guidance, projecting revenue of

Form 8-K Edwards Lifesciences For: Jul 23

Thu, 23 Jul 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260723/26808487.html

Form 8-K Edwards Lifesciences For: Jul 23

Thu, 23 Jul 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260723/26808487.html

Edwards Lifesciences (EW) Tops Q2 EPS by 4c; reaffirms guidance

Thu, 23 Jul 2026 16:19:43 -0400

Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.78, $0.04 better than the analyst estimate of $0.74. Revenue for the quarter came in at $1.74 billion versus the consensus estimate of $1.7 billion.

GUIDANCE:

Edwards Lifesciences sees FY2026 EPS of $2.95-$3.05, versus the consensus of $3.01.

Increasing total company constant currency2 sales growth guidance: 10% to 11% from 9% to 11%
Increasing TAVR constant currency2 sales growth guidance: 8% to 9% from 7% to 9%
Increasing TMTT sales guidance: $760 to $780 million from $740 to $780 million

Expected clinical presentations at TCT: PROGRESS and CLASP IITR
Expected Q4 approvals of PASCAL tricuspid indication

Edwards Lifesciences (EW) Tops Q2 EPS by 4c; reaffirms guidance

Thu, 23 Jul 2026 16:19:43 -0400

GUIDANCE:

Edwards Lifesciences sees FY2026 EPS of $2.95-$3.05, versus the consensus of $3.01.

Expected clinical presentations at TCT: PROGRESS and CLASP IITR
Expected Q4 approvals of PASCAL tricuspid indication

Edwards Lifesciences Reports Second Quarter Results

Thu, 23 Jul 2026 16:15:00 -0400

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026.

Highlights

Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5%
Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5%
Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies
Q2 EPS of $0.421; adjusted2 EPS of $0.781
Recent clinical data at New York Valves reinforce best-in-class SAPIEN performance and durability; PASCAL, EVOQUE and SAPIEN M3 differentiated body of clinical evidence continues to expand

2026 Outlook

Increasing total company constant currency2 sales growth

Edwards Lifesciences Reports Second Quarter Results

Thu, 23 Jul 2026 16:15:00 -0400

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026.

Highlights

Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5%
Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5%
Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies
Q2 EPS of $0.421; adjusted2 EPS of $0.781
Recent clinical data at New York Valves reinforce best-in-class SAPIEN performance and durability; PASCAL, EVOQUE and SAPIEN M3 differentiated body of clinical evidence continues to expand

2026 Outlook

Increasing total company constant currency2 sales growth

Edwards Lifesciences Reports Second Quarter Results

Thu, 23 Jul 2026 16:15:00 -0400

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026.

Highlights

Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5%
Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5%
Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies
Q2 EPS of $0.421; adjusted2 EPS of $0.781
Recent clinical data at New York Valves reinforce best-in-class SAPIEN performance and durability; PASCAL, EVOQUE and SAPIEN M3 differentiated body of clinical evidence continues to expand

2026 Outlook

Increasing total company constant currency2 sales growth

Edwards Lifesciences Reports Second Quarter Results

Thu, 23 Jul 2026 16:15:00 -0400

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026.

Highlights

Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5%
Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5%
Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies
Q2 EPS of $0.421; adjusted2 EPS of $0.781
Recent clinical data at New York Valves reinforce best-in-class SAPIEN performance and durability; PASCAL, EVOQUE and SAPIEN M3 differentiated body of clinical evidence continues to expand

2026 Outlook

Increasing total company constant currency2 sales growth